177Lu-PSMA-3Q

177Lu-PSMA-3Q is a radioligand therapy under investigation for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It consists of lutetium-177, a beta-emitting radioisotope, conjugated to a ligand that targets prostate-specific membrane antigen (PSMA), which is highly expressed on prostate cancer cells. Upon binding to PSMA-expressing tumor cells, the radiolabeled compound delivers targeted radiation, leading to DNA damage and cell death in malignant tissue while sparing most normal tissues. This approach aims to improve outcomes in patients with advanced prostate cancer who have limited treatment options[5]. The specific characteristics or differences between 177Lu-PSMA-3Q and other PSMA-targeted radioligands such as 177Lu-PSMA-617 are not detailed in available sources.